BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28183250)

  • 21. [Targeted therapies and radiation therapy in non-small cell lung cancer].
    Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
    Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives.
    Nappi A; Berretta M; Romano C; Tafuto S; Cassata A; Casaretti R; Silvestro L; Divitiis C; Alessandrini L; Fiorica F; Ottaiano A; Nasti G
    Curr Cancer Drug Targets; 2018; 18(5):421-429. PubMed ID: 28183254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Antibodies in Cancer Therapy.
    Gasser M; Waaga-Gasser AM
    Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On target? Off target? Why we really do not know.
    Leichman L
    J Clin Oncol; 2010 Jun; 28(18):2937-8. PubMed ID: 20458025
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.
    Sankhala KK
    Expert Opin Investig Drugs; 2017 Apr; 26(4):427-443. PubMed ID: 28267385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
    Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
    Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
    Mosquera C; Maglic D; Zervos EE
    Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular targets in GI malignancies - A pathologist's perspective.
    Pawar S; Sharma A
    Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalised Treatment in Gastric Cancer: Myth or Reality?
    Tarazona N; Gambardella V; Huerta M; Roselló S; Cervantes A
    Curr Oncol Rep; 2016 Jul; 18(7):41. PubMed ID: 27215435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melatonin and gastrointestinal cancers: Current evidence based on underlying signaling pathways.
    Pourhanifeh MH; Mehrzadi S; Kamali M; Hosseinzadeh A
    Eur J Pharmacol; 2020 Nov; 886():173471. PubMed ID: 32877658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives.
    Mahmood MQ; Shukla SD; Dua K; Shastri MD
    Curr Pharm Des; 2017; 23(16):2314-2320. PubMed ID: 28120720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
    Kondo T
    Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gastrointestinal stromal tumors: a new model for target therapy].
    Tonini G; Vincenzi B; La Cesa A
    Clin Ter; 2003; 154(2):75-6. PubMed ID: 12856363
    [No Abstract]   [Full Text] [Related]  

  • 39. Aurora kinase A in gastrointestinal cancers: time to target.
    Katsha A; Belkhiri A; Goff L; El-Rifai W
    Mol Cancer; 2015 May; 14():106. PubMed ID: 25987188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.
    Alturkmani HJ; Pessetto ZY; Godwin AK
    Expert Opin Investig Drugs; 2015; 24(8):1045-58. PubMed ID: 26098203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.